First Wave up as FDA reviews pancreatic drug trial application

GridAI Technologies

13/01/2023 22:20

** Shares of First Wave BioPharma  FWBI.O  rise as much as
~52% to 99 cents after the bell
    ** FWBI says U.S. Food and Drug Administration is reviewing
co's application requesting authorization for human trials for a
new formulation of its experimental drug  urn:newsml:reuters.com:*:nGNX4s8pSr
    ** Co is evaluating the drug, adrulipase, as a potential
treatment for a type of pancreatic disorder associated with
cystic fibrosis and chronic pancreatitis
    ** FWBI says it has been in discussions with FDA and expects
a "forthcoming response" around the end of January
    ** As of last close, FWBI had fallen ~98% in the past 12
months 
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))